Keyword: Cyramza

An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.

Adding Cyramza to Roche’s Tarceva stalled tumor progression by 19.4 months, a seven-month improvement over Tarceva alone.

After Eli Lilly’s Cyramza flopped a liver cancer trial five years ago, the drugmaker’s chances in the field looked slim. That all changed Monday.

Lilly Oncology’s marketing chief has some key words for pharma marketers: Don’t lead with data. Put patients’ insights at the forefront instead.

Eli Lilly's oncology president Sue Mahony plans to retire at the end of August after 18 years with the drugmaker.

After Lilly’s Cyramza flopped a liver cancer trial in 2014, the company designed a trial for a specific subpopulation. Now, it’s back with a win.

Eli Lilly is aiming for $23 billion in 2018 revenue, but it'll have to contend with a tough environment in diabetes and one hefty patent expiration.

In just a few years, pharma's top launches of 2014 have amassed huge sales and reshaped treatment—and they're now among the biggest launches ever.

ESMO's research slate included some truly late-breaking data, plus numbers from some closely watched trials. Here's your need-to-know.

Industry-watchers have known since may that Eli Lilly's Cyramza had topped placebo at holding off bladder cancer. But they didn’t know how much.